Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 51 - 100 out of 12,713

Document Document Title
WO/2020/257429A1
The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.  
WO/2020/253872A1
2-Benzylidene hydrazinoadenosine compounds having A2A adenosine receptor agonistic activity, represented by a general formula (I) and pharmaceutical compositions containing the same. The compounds and compositions may act as A2A adenosin...  
WO/2020/256084A1
A crystal of a compound represented by formula 5. In formula 5, R1 represents a hydroxyl protecting group, and R2 represents a leaving group.  
WO/2020/255978A1
[Problem] To provide a novel phosphate ester compound having a pyrrolopyrimidine skeleton or a pharmaceutically acceptable salt thereof which has excellent antitumor effects, and a method for preventing and/or treating a tumor that is us...  
WO/2020/253866A1
The present invention relates to a compound represented by formula I or a pharmaceutically acceptable salt, stereoisomeride, pharmaceutically acceptable hydrate or solvate, or pharmaceutically acceptable ester thereof, wherein R is selec...  
WO/2020/253867A1
The present application provides a small-molecule compound, represented by general formula (I), having A2A adenosine receptor antagonistic activity and a pharmaceutical composition containing same. The compound and composition can be use...  
WO/2020/253870A1
The present disclosure provides 6-hydrazinoadenosine having A2A adenosine receptor agonistic activity represented by general formula (I) and a derivative thereof, and a pharmaceutical composition containing same. The compound and composi...  
WO/2020/257283A1
The disclosure provides nicotinamide riboside (NR), the reduced form of NR (NRH), nicotinic acid riboside (NAR), the reduced form of NAR (NARH), derivatives thereof, compositions thereof and uses thereof. The NR and NAR derivatives have ...  
WO/2020/255979A1
[Problem] To provide: a novel carbonate compound of nucleotides which has a pyrrolopyrimidine skeleton and exhibits an excellent antitumor effect, or a pharmaceutically acceptable salt thereof; and a method for preventing and/or treating...  
WO/2020/248068A1
The present application provides a synthetic method for production of 3-azido-3-deoxy-D-galactopyranose. Also provided are methods of using the 3-azido-3-deoxy-D-galactopyranose in the manufacture of galactoside galectin antagonists, suc...  
WO/2020/252380A2
The present disclosure is concerned with 2,4,7-substituted-7-deaza-2'-deoxy-2'- fluoroarabinosyl nucleoside and nucleotide prodrugs that are capable of inhibiting viral infections and methods of treating viral infections such as, for exa...  
WO/2020/245191A1
The present invention provides compounds and compositions containing reduced nicotinamide riboside for use in methods of prevention and/or treatment of skeletal muscle disease and/or conditions. In one embodiment of the invention, said c...  
WO/2020/247818A1
Disclosed herein are compositions and pharmaceutical formulations that comprise a binding moiety conjugated to a modified polynucleic acid molecule and a polymer. Also described herein include methods for treating a disease which utilize...  
WO/2020/246616A1
[Problem] To provide a novel fluorescent probe. [Solution] The compound represented by general formula (I), or a salt thereof.  
WO/2020/247546A1
The disclosure provides adenosine analogs for the treatment of disease such as pain and inflammatory conditions.  
WO/2020/247782A1
Disclosed herein are compositions and pharmaceutical formulations that comprise a binding moiety conjugated to a modified polynucleic acid molecule and a polymer. Also described herein include methods for treating a cancer which utilize ...  
WO/2020/235658A1
Provided are a multi-fluorous blockmer capable of reducing the purification burden using a readily available fluorous tag, and an oligonucleotide synthesis method using the same. A multi-fluorous blockmer represented by the formula is sy...  
WO/2020/227132A1
Provided herein are prodrugs of 5-fluorodeoxyuridine monophosphate compounds, compositions thereof, methods of their preparation, and their use in treating cancers. In another aspect, provided herein is a pharmaceutical composition compr...  
WO/2020/227421A1
Provided herein are compounds of Formula (I), Formula (II) and/or Formula (III), or pharmaceutically acceptable salts of any of the foregoing, pharmaceutical compositions that include a compound described herein (including pharmaceutical...  
WO/2020/223530A1
Provided herein are phosphorylated gemcitabine derivative prodrug compounds, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of cancer.  
WO/2020/221209A1
A CD73 inhibitor having the structure represented by formula (I), a preparation method therefor and an application thereof. The series of compounds can be widely applied in the preparation of drugs for treating cancers or tumors that are...  
WO/2020/219417A1
Compounds, compositions, and methods for treating and/or preventing at least one disease, disorder, and/or condition associated with E-selectin, galectin-3, and/or CXCR4 chemokine receptor activity are disclosed herein. For example, mult...  
WO/2020/219464A1
Provided herein are cyclic phosphate compounds, their preparation and their uses, such as treating liver diseases or conditions or a disease or condition in which the physiological or pathogenic pathways involve the liver.  
WO/2020/216326A1
The disclosure provides compounds of formula (I), wherein R1, R2, R5, R6, R7, L1, L2, W1, W2, and Z1 are as defined herein, and compositions comprising same, and methods related to activating alpha-kinase 1 (ALPK1) for modulating an immu...  
WO/2020/216646A1
Disclosed herein are nucleoside derivatives, cytidine derivatives and Gemcitabine derivatives and methods of forming nucleoside derivatives, cytidine derivatives and Gemcitabine derivatives.  
WO/2020/214589A1
Modified nucleotides, such as α-phosphoseleno-nucleotides (dNTPαSe and NTPαSe), can be incorporated into nucleic acids by enzymatic processes in a similar manner as naturally occurring nucleotides. Altering the properties of modified ...  
WO/2020/211672A1
The present disclosure relates generally to compounds that are inhibitors of CD73 and are useful in treating CD73-associated diseases or conditions. Compositions containing the compounds of the present disclosure are also provided.  
WO/2020/210970A1
The present disclosure relates generally to imidazotriazine derivatives that are inhibitors of CD73 and are useful in treating CD73-associated diseases or conditions. Compositions containing the compounds of the present disclosure are al...  
WO/2020/212301A1
The present invention relates to an optimized method for preparing a P(V) monomer of formula (IIIa) or (IIIb) from a nucleoside using DBU as a base at about 0.8 equivalent to nucleoside.  
WO/2020/176741A9
Provided are methods of treating multiple sclerosis, which comprises administering to a patient a therapeutically effective amount of DNA methylation blocker. Also provided are method of retarding development of multiple sclerosis by adm...  
WO/2020/203896A1
The present invention addresses the problem of providing a new artificial nucleic acid, a production method therefor, and a use thereof. The problem can be solved by an artificial nucleic acid having a unit derived from a compound repres...  
WO/2020/204022A1
Provided is a method for manufacturing a compound represented by formula (III) by using, as a material, a compound represented by formula (I).  
WO/2020/201751A1
The present invention relates to salts of triphosphate phosphoramidates which are useful in the treatment of cancer.  
WO/2020/193765A1
Embodiments of the present disclosure relate to nucleotides labeled with photoswitchable compounds. Also provided herein are methods and kits of using these labeled nucleotides for sequencing applications.  
WO/2020/198266A1
The present disclosure relates to compounds of Formula (I), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.  
WO/2020/197882A1
The invention relates to compounds and compositions for modulation of nicotinamide adenine dinucleotide (NAD+). The invention also relates to methods of making such compounds and compositions. The invention relates to pharmaceutical comp...  
WO/2020/190073A1
The present invention relates to a pharmaceutical composition for the prophylaxis or treatment of cancer comprising a novel azolopyrimidine heterocyclic compound as an active ingredient, and the pharmaceutical composition for the prophyl...  
WO/2020/190703A1
The present application provides methods for treating wounds by administering a combination of nicotinamide riboside and pterostilbene. The compositions can be administered orally or as a topical formulation.  
WO/2020/188288A1
The present invention relates to compounds of Formula (I) for use in the treatment of nervous system disorders and pain, wherein Formula (I) is: formula(I) or a pharmaceutically acceptable salt or isomer thereof, wherein R is defined her...  
WO/2020/191252A1
Among other things, the present disclosure provides technologies for oligonucleotide preparation, particularly chirally controlled oligonucleotide preparation, which technologies provide greatly improved crude purity and yield, and signi...  
WO/2020/186588A1
Disclosed is a crystal form A of a 2'-fluoro-4'-substituted nucleoside analog I, wherein same falls within the field of pharmaceutical chemistry. The crystal form A has the following structure: (I). The CuKα-XRPD pattern of the crystal ...  
WO/2020/184677A1
The present invention addresses the problem of providing an anti-hepatitis B virus agent and a prophylactic or therapeutic agent for hepatitis B virus-associated diseases, containing a nucleic acid analog as an active ingredient. The pro...  
WO/2020/186124A1
The present disclosure provides modified microRNA nucleic acid compositions that have one or more cytosine and/or uracil bases replaced with gemcitabine or a 5-halouracil, respectively. More specifically, the present disclosure reveals t...  
WO/2020/178162A1
The present application relates to exocyclic amine-substituted coumarin derivatives and their uses as fluorescent labels. These compounds may be used as fluorescent labels for nucleotides in nucleic acid sequencing applications.  
WO/2020/178767A1
The invention relates to compounds of Formula (I), salts thereof, pharmaceutical compositions thereof, as well as methods of treating or preventing HIV in subjects.  
WO/2020/178768A1
The present disclosure relates to 3'3'-cyclic dinucleotides comprising a carbocyclic nucleotide and derivatives thereof, that can modulate the activity of the STING adaptor protein.  
WO/2020/177420A1
Disclosed is an ultrasonic composite acidic water extraction method for a Cordyceps polysaccharide and cordycepin in Cordyceps militaris, which falls within the technical field of food processing. The method comprises: picking, washing, ...  
WO/2020/178165A1
The present application relates to tertiary amine substituted coumarin derivatives of formula (I) and their uses as fluorescent labels. These compounds may be used as fluorescent labels for nucleotides in nucleic acid sequencing applicat...  
WO/2020/176741A1
Provided are methods of treating multiple sclerosis, which comprises administering to a patient a therapeutically effective amount of DNA methylation blocker. Also provided are method of retarding development of multiple sclerosis by adm...  
WO/2020/169696A1
The invention relates to a compound of formula (II) wherein X, Y, R5, Rx, Ry and Nu are as defined in the description and in the claims. The compound of formula (II) can be used in the manufacture of medicaments.  

Matches 51 - 100 out of 12,713